Nautilus Biotechnology annual stock-based compensation
2020
2021
2022
2023
2024
2025
Nautilus Biotechnology Stock-Based Compensation Growth & History (NAUT)
Nautilus Biotechnology's stock-based compensation was $6.8M for fiscal 2025.
View full Nautilus Biotechnology company overviewNautilus Biotechnology annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.8M | −$5.9M | −46.11% |
| 2024 | 2024-12-31 | $12.7M | $564,000 | +4.65% |
| 2023 | 2023-12-31 | $12.1M | $1.8M | +16.93% |
| 2022 | 2022-12-31 | $10.4M | $2.4M | +30.83% |
| 2021 | 2021-12-31 | $7.9M | $7.6M | +2050.14% |
| 2020 | 2020-12-31 | $369,000 | — | — |
Nautilus Biotechnology quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.2M | −$551,000 | −32.24% |
| Q1 2026 | 2026-03-31 | $1.4M | −$806,000 | −37.18% |
| Q4 2025 | 2025-12-31 | $1.5M | −$1.7M | −52.91% |
| Q3 2025 | 2025-09-30 | $1.5M | −$1.7M | −53.02% |
| Q2 2025 | 2025-06-30 | $1.7M | −$1.6M | −47.88% |
| Q1 2025 | 2025-03-31 | $2.2M | −$946,000 | −30.38% |
| Q4 2024 | 2024-12-31 | $3.1M | $51,000 | +1.66% |
| Q3 2024 | 2024-09-30 | $3.2M | $78,000 | +2.51% |
| Q2 2024 | 2024-06-30 | $3.3M | $181,000 | +5.84% |
| Q1 2024 | 2024-03-31 | $3.1M | $254,000 | +8.88% |
| Q4 2023 | 2023-12-31 | $3.1M | $240,000 | +8.47% |
| Q3 2023 | 2023-09-30 | $3.1M | $236,000 | +8.22% |
| Q2 2023 | 2023-06-30 | $3.1M | $531,000 | +20.69% |
| Q1 2023 | 2023-03-31 | $2.9M | $750,000 | +35.55% |
| Q4 2022 | 2022-12-31 | $2.8M | $303,000 | +11.98% |
| Q3 2022 | 2022-09-30 | $2.9M | $622,000 | +27.67% |
| Q2 2022 | 2022-06-30 | $2.6M | $747,000 | +41.04% |
| Q1 2022 | 2022-03-31 | $2.1M | $774,000 | +57.93% |
| Q4 2021 | 2021-12-31 | $2.5M | — | — |
| Q3 2021 | 2021-09-30 | $2.2M | $2.2M | +3710.17% |
| Q2 2021 | 2021-06-30 | $1.8M | — | — |
| Q1 2021 | 2021-03-31 | $1.3M | — | — |
| Q3 2020 | 2020-09-30 | $59,000 | — | — |
Nautilus Biotechnology stock-based compensation trends
Over the last five fiscal years, Nautilus Biotechnology's stock-based compensation increased from $369,000 to $6.8M, a change of $6.5M. The latest reported quarter, Q2 2026, shows $1.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nautilus Biotechnology source filings ↗